Navigation Links
Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
Date:12/6/2009

relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, is currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar(®) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated benefits of the acquisition of Proteolix and the timing, progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including the risk that Proteolix's operations will not be integrated successfully into Onyx's, the risk that Onyx may not realize the anticipated benefits of the acquisition and risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release excep
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. More proof needed of safety and quality of electronic personal health records
3. Back to School Means Backpack Safety
4. Seniors Need a Safety Plan in Face of Disasters
5. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
6. National Patient Safety Foundation Partners with Vocera Communications
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... its potentially harmful effects in children, codeine continues to ... research from UCSF Benioff Children,s Hospital San Francisco. , ... , solutions include changing provider prescription behaviors to promote ... ibuprofen or hydrocodone. , "Despite strong evidence against the ... be prescribed to large numbers of them each year," ...
(Date:4/18/2014)... 2014) -- A group of scientists from the ... Sanders-Brown Center on Aging has found interesting new ... function in Parkinson,s disease (PD). , Published ... study, which assessed cognitive function in depressed and ... replacement therapy commonly used to treat motor symptoms ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Treating depression in PD patients: New research 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3
... Confirms Part D Seniors Also Enjoy Broad Choice of,Prescription ... Association (PCMA) issued the following statement on new budget,figures ... is lower over the,next ten years than was estimated ... without sacrificing beneficiaries,choice of prescription drugs. New budget documents ...
... Nursing Home Care to Face,Severe Resistance, JOPLIN, Mo., ... today reporting the Bush Administration plans to cut,U.S. seniors, ... to,be unveiled Monday, the Coalition to Protect Senior Care ... as it did last summer and fall when the,Coalition ...
... Mettler-Toledo,International Inc. (NYSE: MTD ) today announced ... fourth-quarter results on Thursday, February,7, 2008 at 5:00 p.m. ... call,visit http://www.mt.com/investors on the Company,s website. A ... 2008., METTLER TOLEDO is a leading global supplier ...
... off Sponsorship of Living ... Aid Retired NFL Players, PHOENIX, Jan. 31 Retired ... are more than twice as likely,as the general population to ... stroke and other cardiovascular (CV) diseases, according to,a recent study ...
... Ill., Jan. 31 Horace Mann,Educators Corporation (NYSE: ... Wednesday, February 6, 2008 after the market closes. The,earnings ... Relations section of the Company,s website at http://www.horacemann.com ... financial results on,Thursday, February 7, 2008 at 10:00 a.m. ...
... 31 National opinion leaders will,convene in Arlington, ... data,guidelines, practical applications, and strategies for the treatment ... make the,meeting highly interactive., The Summit will ... sponsored,by The Dannemiller Educational Foundation, and the content ...
Cached Medicine News:Health News:Coalition to Protect Senior Care Gearing Up to Fight Bush Administration Medicare Cuts 2Health News:NFL Linemen Predisposed to Cardiovascular Disease; Early Detection is Key to Getting and Staying Healthy 2Health News:NFL Linemen Predisposed to Cardiovascular Disease; Early Detection is Key to Getting and Staying Healthy 3Health News:Horace Mann Announces Fourth Quarter Earnings Release and Conference Call 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 3
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...
... UVIDEM was well-tolerated with signs of durable,disease control ... 05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented ... vaccine clinical trial (DC-MEL-202). The,results showed that UVIDEM ... of immune response in patients with,progressive metastatic melanoma. ...
Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: